Skip to main content
Top
Published in: BMC Infectious Diseases 1/2014

Open Access 01-12-2014 | Research article

The potential impact of expanding target age groups for polio immunization campaigns

Authors: Radboud J Duintjer Tebbens, Dominika A Kalkowska, Steven GF Wassilak, Mark A Pallansch, Stephen L Cochi, Kimberly M Thompson

Published in: BMC Infectious Diseases | Issue 1/2014

Login to get access

Abstract

Background

Global efforts to eradicate wild polioviruses (WPVs) continue to face challenges due to uninterrupted endemic WPV transmission in three countries and importation-related outbreaks into previously polio-free countries. We explore the potential role of including older children and adults in supplemental immunization activities (SIAs) to more rapidly increase population immunity and prevent or stop transmission.

Methods

We use a differential equation-based dynamic poliovirus transmission model to analyze the epidemiological impact and vaccine resource implications of expanding target age groups in SIAs. We explore the use of older age groups in SIAs for three situations: alternative responses to the 2010 outbreak in Tajikistan, retrospective examination of elimination in two high-risk states in northern India, and prospective and retrospective strategies to accelerate elimination in endemic northwestern Nigeria. Our model recognizes the ability of individuals with waned mucosal immunity (i.e., immunity from a historical live poliovirus infection) to become re-infected and contribute to transmission to a limited extent.

Results

SIAs involving expanded age groups reduce overall caseloads, decrease transmission, and generally lead to a small reduction in the time to achieve WPV elimination. Analysis of preventive expanded age group SIAs in Tajikistan or prior to type-specific surges in incidence in high-risk areas of India and Nigeria showed the greatest potential benefits of expanded age groups. Analysis of expanded age group SIAs in outbreak situations or to accelerate the interruption of endemic transmission showed relatively less benefit, largely due to the circulation of WPV reaching individuals sooner or more effectively than the SIAs. The India and Nigeria results depend strongly on how well SIAs involving expanded age groups reach relatively isolated subpopulations that sustain clusters of susceptible children, which we assume play a key role in persistent endemic WPV transmission in these areas.

Conclusions

This study suggests the need to carefully consider the epidemiological situation in the context of decisions to use expanded age group SIAs. Subpopulations of susceptible individuals may independently sustain transmission, which will reduce the overall benefits associated with using expanded age group SIAs to increase population immunity to a sufficiently high level to stop transmission and reduce the incidence of paralytic cases.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sutter RW, Kew OM, Cochi SL: Poliovirus vaccine -- live. Vaccines. Fifth edition. Edited by: Plotkin SA, Orenstein WA, Offit PA. 2008, Philadelphia: Saunders Elsevier Sutter RW, Kew OM, Cochi SL: Poliovirus vaccine -- live. Vaccines. Fifth edition. Edited by: Plotkin SA, Orenstein WA, Offit PA. 2008, Philadelphia: Saunders Elsevier
2.
go back to reference World Health Organization: Transmission of wild poliovirus type 2 - apparent global interruption. Wkly Epidemiol Rec. 2001, 76: 95-97. World Health Organization: Transmission of wild poliovirus type 2 - apparent global interruption. Wkly Epidemiol Rec. 2001, 76: 95-97.
4.
go back to reference Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SGF, Cochi SL: Modeling population immunity to support efforts to end the transmission of live polioviruses. Risk Anal. 2013, 33: 647-663. 10.1111/j.1539-6924.2012.01891.x.CrossRefPubMed Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SGF, Cochi SL: Modeling population immunity to support efforts to end the transmission of live polioviruses. Risk Anal. 2013, 33: 647-663. 10.1111/j.1539-6924.2012.01891.x.CrossRefPubMed
5.
go back to reference World Health Assembly: Poliomyelitis: intensification of the global eradication initiative (resolution 65.5). 2012, Geneva, Switzerland: World Health Organization World Health Assembly: Poliomyelitis: intensification of the global eradication initiative (resolution 65.5). 2012, Geneva, Switzerland: World Health Organization
6.
go back to reference Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SG, Kim J-H, Cochi SL: Pre-eradication vaccine policy options for poliovirus infection and disease control. Risk Anal. 2013, 33: 516-543. 10.1111/risa.12019.CrossRefPubMed Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SG, Kim J-H, Cochi SL: Pre-eradication vaccine policy options for poliovirus infection and disease control. Risk Anal. 2013, 33: 516-543. 10.1111/risa.12019.CrossRefPubMed
7.
go back to reference Hull HF, Ward NA, Hull BP, Milstien J, de Quadros CA: Paralytic poliomyelitis: seasoned strategies, disappearing disease. Lancet. 1994, 343: 1331-1337. 10.1016/S0140-6736(94)92472-4.CrossRefPubMed Hull HF, Ward NA, Hull BP, Milstien J, de Quadros CA: Paralytic poliomyelitis: seasoned strategies, disappearing disease. Lancet. 1994, 343: 1331-1337. 10.1016/S0140-6736(94)92472-4.CrossRefPubMed
8.
go back to reference World Health Organization: Global polio eradication initiative: polio eradication and endgame strategic plan (2013–2018). 2013, Geneva, Switzerland: World Health Organization, Report No.: WHO/POLIO/13.02 World Health Organization: Global polio eradication initiative: polio eradication and endgame strategic plan (2013–2018). 2013, Geneva, Switzerland: World Health Organization, Report No.: WHO/POLIO/13.02
9.
go back to reference Sabin AB, Ramos-Alvarez M, Alvarez-Amezquita J, Pelon W, Michaels RH, Spigland I, Koch MA, Barnes JM JSR: Live, orally given poliovirus vaccine: effects of rapid mass immunization on population under conditions of massive enteric infection with other viruses. JAMA. 1960, 173: 1521-1526. 10.1001/jama.1960.03020320001001.CrossRefPubMed Sabin AB, Ramos-Alvarez M, Alvarez-Amezquita J, Pelon W, Michaels RH, Spigland I, Koch MA, Barnes JM JSR: Live, orally given poliovirus vaccine: effects of rapid mass immunization on population under conditions of massive enteric infection with other viruses. JAMA. 1960, 173: 1521-1526. 10.1001/jama.1960.03020320001001.CrossRefPubMed
10.
go back to reference Olive JM, Risi JB, de Quadros CA: National immunization days: experience in Latin America. J Infect Dis. 1997, 175 (1): S189-S193.CrossRefPubMed Olive JM, Risi JB, de Quadros CA: National immunization days: experience in Latin America. J Infect Dis. 1997, 175 (1): S189-S193.CrossRefPubMed
11.
go back to reference Más Lago P: Eradication of poliomyelitis in Cuba: a historical perspective. Bull World Health Organ. 1999, 77: 681-687.PubMedPubMedCentral Más Lago P: Eradication of poliomyelitis in Cuba: a historical perspective. Bull World Health Organ. 1999, 77: 681-687.PubMedPubMedCentral
12.
go back to reference Risi JB: The control of poliomyelitis in Brazil. Rev Infect Dis. 1984, 6: S400-S403. 10.1093/clinids/6.Supplement_2.S400.CrossRef Risi JB: The control of poliomyelitis in Brazil. Rev Infect Dis. 1984, 6: S400-S403. 10.1093/clinids/6.Supplement_2.S400.CrossRef
13.
go back to reference Prevots DR, Atti ML C d, Sallabanda A, Diamanti E, Aylward RB, Kakariqqi E, Fiore L, Ylli A, van der Avoort HG, Sutter RW, et al: Outbreak of paralytic poliomyelitis in Albania, 1996: high attack rate among adults and apparent interruption of transmission following nationwide mass vaccination. Clin Infect Dis. 1998, 26: 419-425. 10.1086/516312.CrossRefPubMed Prevots DR, Atti ML C d, Sallabanda A, Diamanti E, Aylward RB, Kakariqqi E, Fiore L, Ylli A, van der Avoort HG, Sutter RW, et al: Outbreak of paralytic poliomyelitis in Albania, 1996: high attack rate among adults and apparent interruption of transmission following nationwide mass vaccination. Clin Infect Dis. 1998, 26: 419-425. 10.1086/516312.CrossRefPubMed
14.
go back to reference Centers for Disease Control and Prevention: Outbreaks following wild poliovirus importations --- Europe, Africa, and Asia, January 2009-September 2010. Morb Mortal Wkly Rep. 2010, 59: 1393-1399. Centers for Disease Control and Prevention: Outbreaks following wild poliovirus importations --- Europe, Africa, and Asia, January 2009-September 2010. Morb Mortal Wkly Rep. 2010, 59: 1393-1399.
15.
go back to reference Gregory CJ, Ndiaye S, Patel M, Hakizamana E, Wannemuehler K, Ndinga E, Chu S, Talani P, Kretsinger K: Investigation of elevated case-fatality rate in poliomyelitis outbreak in Pointe Noire, Republic of Congo, 2010. Clin Infect Dis. 2012, 55: 1299-1306. 10.1093/cid/cis715.CrossRefPubMed Gregory CJ, Ndiaye S, Patel M, Hakizamana E, Wannemuehler K, Ndinga E, Chu S, Talani P, Kretsinger K: Investigation of elevated case-fatality rate in poliomyelitis outbreak in Pointe Noire, Republic of Congo, 2010. Clin Infect Dis. 2012, 55: 1299-1306. 10.1093/cid/cis715.CrossRefPubMed
16.
go back to reference World Health Organization: Outbreak news. Poliomyelitis, Namibia. Wkly Epidemiol Rec. 2006, 81: 238- World Health Organization: Outbreak news. Poliomyelitis, Namibia. Wkly Epidemiol Rec. 2006, 81: 238-
17.
go back to reference Oostvogel P, van Wijngaarden J, van der Avoort HG, Mulders MN, Conyn-van Spaendonck MA, Rümke H, van Steenis G, van Loon AM: Poliomyelitis outbreak in an unvaccinated community in The Netherlands, 1992–3. Lancet. 1994, 344: 665-670. 10.1016/S0140-6736(94)92091-5.CrossRefPubMed Oostvogel P, van Wijngaarden J, van der Avoort HG, Mulders MN, Conyn-van Spaendonck MA, Rümke H, van Steenis G, van Loon AM: Poliomyelitis outbreak in an unvaccinated community in The Netherlands, 1992–3. Lancet. 1994, 344: 665-670. 10.1016/S0140-6736(94)92091-5.CrossRefPubMed
18.
go back to reference Thompson KM, Duintjer Tebbens RJ: Eradication versus control for poliomyelitis: an economic analysis. Lancet. 2007, 369: 1363-1371. 10.1016/S0140-6736(07)60532-7.CrossRefPubMed Thompson KM, Duintjer Tebbens RJ: Eradication versus control for poliomyelitis: an economic analysis. Lancet. 2007, 369: 1363-1371. 10.1016/S0140-6736(07)60532-7.CrossRefPubMed
19.
go back to reference Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SGF, Linkins J, Sutter RW, Aylward RB, Thompson KM: Economic analysis of the global polio eradication initiative. Vaccine. 2011, 29: 334-343.CrossRef Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SGF, Linkins J, Sutter RW, Aylward RB, Thompson KM: Economic analysis of the global polio eradication initiative. Vaccine. 2011, 29: 334-343.CrossRef
20.
go back to reference Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SG, Cochi SL, Thompson KM: Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses. Risk Anal. 2013, 23: 703-749.CrossRef Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SG, Cochi SL, Thompson KM: Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses. Risk Anal. 2013, 23: 703-749.CrossRef
21.
go back to reference Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, et al: Expert review on poliovirus immunity and transmission. Risk Anal. 2013, 33: 544-605. 10.1111/j.1539-6924.2012.01864.x.CrossRefPubMed Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, et al: Expert review on poliovirus immunity and transmission. Risk Anal. 2013, 33: 544-605. 10.1111/j.1539-6924.2012.01864.x.CrossRefPubMed
22.
go back to reference Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, et al: Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs. Risk Anal. 2013, 33: 606-646. 10.1111/risa.12031.CrossRefPubMed Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, et al: Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs. Risk Anal. 2013, 33: 606-646. 10.1111/risa.12031.CrossRefPubMed
23.
go back to reference Sterman J: Business dynamics: systems thinking and modeling for a complex world. 2001, Boston, MA: McGraw-Hill Sterman J: Business dynamics: systems thinking and modeling for a complex world. 2001, Boston, MA: McGraw-Hill
24.
go back to reference Lloyd AL: Realistic distributions of infectious periods in epidemic models: changing patterns of persistence and dynamics. Theor Popul Biol. 2001, 60: 59-71. 10.1006/tpbi.2001.1525.CrossRefPubMed Lloyd AL: Realistic distributions of infectious periods in epidemic models: changing patterns of persistence and dynamics. Theor Popul Biol. 2001, 60: 59-71. 10.1006/tpbi.2001.1525.CrossRefPubMed
25.
go back to reference Duintjer Tebbens RJ, Pallansch MA, Kim J-H, Burns CC, Kew OM, Oberste MS, Diop O, Wassilak SGF, Cochi SL, Thompson KM: Review: oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal. 2013, 23: 680-702.CrossRef Duintjer Tebbens RJ, Pallansch MA, Kim J-H, Burns CC, Kew OM, Oberste MS, Diop O, Wassilak SGF, Cochi SL, Thompson KM: Review: oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal. 2013, 23: 680-702.CrossRef
28.
go back to reference Centers for Disease Control and Prevention: Update on vaccine-derived polioviruses--worldwide, July 2009-March 2011. MMWR Morb Mortal Wkly Rep. 2011, 60: 846-850. Centers for Disease Control and Prevention: Update on vaccine-derived polioviruses--worldwide, July 2009-March 2011. MMWR Morb Mortal Wkly Rep. 2011, 60: 846-850.
29.
go back to reference World Health Organization: Summary of discussions and recommendations, 16th informal consultation of the global polio laboratory network, 22–23 September 2010, WHO/HQ. 2010, Geneva, Switzerland: World Health Organization World Health Organization: Summary of discussions and recommendations, 16th informal consultation of the global polio laboratory network, 22–23 September 2010, WHO/HQ. 2010, Geneva, Switzerland: World Health Organization
30.
go back to reference Wassilak SGF, Pate MA, Wannemuehler K, Jenks J, Burns C, Chenoweth P, Abanida EA, Adu F, Baba M, Gasasira A, et al: Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and widespread circulation in an underimmunized population. J Infect Dis. 2011, 203: 898-909. 10.1093/infdis/jiq140.CrossRefPubMedPubMedCentral Wassilak SGF, Pate MA, Wannemuehler K, Jenks J, Burns C, Chenoweth P, Abanida EA, Adu F, Baba M, Gasasira A, et al: Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and widespread circulation in an underimmunized population. J Infect Dis. 2011, 203: 898-909. 10.1093/infdis/jiq140.CrossRefPubMedPubMedCentral
31.
go back to reference Nathanson N, Kew OM: From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol. 2010, 172: 1213-1229. 10.1093/aje/kwq320.CrossRefPubMedPubMedCentral Nathanson N, Kew OM: From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol. 2010, 172: 1213-1229. 10.1093/aje/kwq320.CrossRefPubMedPubMedCentral
32.
go back to reference Thompson KM, Duintjer Tebbens RJ, Pallansch MA: Evaluation of response scenarios to potential polio outbreaks using mathematical models. Risk Anal. 2006, 26: 1541-1556. 10.1111/j.1539-6924.2006.00843.x.CrossRefPubMed Thompson KM, Duintjer Tebbens RJ, Pallansch MA: Evaluation of response scenarios to potential polio outbreaks using mathematical models. Risk Anal. 2006, 26: 1541-1556. 10.1111/j.1539-6924.2006.00843.x.CrossRefPubMed
33.
go back to reference Giwa FJ, Olayinka AT, Ogunshola FT: Seroprevalence of poliovirus antibodies amongst children in Zaria, Northern Nigeria. Vaccine. 2012, 30: 6759-6765. 10.1016/j.vaccine.2012.09.023.CrossRefPubMed Giwa FJ, Olayinka AT, Ogunshola FT: Seroprevalence of poliovirus antibodies amongst children in Zaria, Northern Nigeria. Vaccine. 2012, 30: 6759-6765. 10.1016/j.vaccine.2012.09.023.CrossRefPubMed
34.
go back to reference Abbink F, Buisman AM, Doornbos G, Woldman J, Kimman TG, Conyn-van Spaendonck MAE: Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion. J Infect Dis. 2005, 191: 990-999. 10.1086/427810.CrossRefPubMed Abbink F, Buisman AM, Doornbos G, Woldman J, Kimman TG, Conyn-van Spaendonck MAE: Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion. J Infect Dis. 2005, 191: 990-999. 10.1086/427810.CrossRefPubMed
35.
go back to reference Glezen PW, McCollough RH, Lamb GA, Chin TDY: Quantitative relationship of preexisting homotypic antibodies to excretion of poliovirus types 1, 2, and 3 following the feeding of trivalent attenuated poliovirus vaccine. Am J Epidemiol. 1969, 90: 146-156.PubMed Glezen PW, McCollough RH, Lamb GA, Chin TDY: Quantitative relationship of preexisting homotypic antibodies to excretion of poliovirus types 1, 2, and 3 following the feeding of trivalent attenuated poliovirus vaccine. Am J Epidemiol. 1969, 90: 146-156.PubMed
36.
go back to reference Glezen WP, Lamb GA, Belden EA, Chin TD: Quantitative relationship of preexisting homotypic antibodies to the excretion of attenuated poliovirus type 1. Am J Epidemiol. 1966, 83: 224-237.PubMed Glezen WP, Lamb GA, Belden EA, Chin TD: Quantitative relationship of preexisting homotypic antibodies to the excretion of attenuated poliovirus type 1. Am J Epidemiol. 1966, 83: 224-237.PubMed
37.
go back to reference Smith JWG, Lee JA, Fletcher WB, Yetts R, Magrath DI, Perkins FT: The response to oral poliovaccine in persons aged 16–18 years. Journal of Hygiene Cambridge. 1976, 76: 235-247. 10.1017/S0022172400055133.CrossRef Smith JWG, Lee JA, Fletcher WB, Yetts R, Magrath DI, Perkins FT: The response to oral poliovaccine in persons aged 16–18 years. Journal of Hygiene Cambridge. 1976, 76: 235-247. 10.1017/S0022172400055133.CrossRef
38.
go back to reference Siegert R, Enders-Ruckle G, Oehme J, Waller D: Der einfluß der prävakzinalen immunität auf die virusausscheidung und antikörperproduktion nach polio-schluckimpfung mit Typ I (Sabin) [the effect of prevaccinal immunity on virus excretion and antibody production after polio immunization with type I (Sabin)]. Deutsche medizinische Wochenschrift. 1963, 88: 1586-1594. 10.1055/s-0028-1112269.CrossRefPubMed Siegert R, Enders-Ruckle G, Oehme J, Waller D: Der einfluß der prävakzinalen immunität auf die virusausscheidung und antikörperproduktion nach polio-schluckimpfung mit Typ I (Sabin) [the effect of prevaccinal immunity on virus excretion and antibody production after polio immunization with type I (Sabin)]. Deutsche medizinische Wochenschrift. 1963, 88: 1586-1594. 10.1055/s-0028-1112269.CrossRefPubMed
39.
go back to reference Mayer BT, Eisenberg JN, Henry CJ, Gomes MG, Ionides EL, Koopman JS: Successes and shortcomings of polio eradication: a transmission modeling analysis. Am J Epidemiol. 2013, 177: 1236-1245. 10.1093/aje/kws378.CrossRefPubMedPubMedCentral Mayer BT, Eisenberg JN, Henry CJ, Gomes MG, Ionides EL, Koopman JS: Successes and shortcomings of polio eradication: a transmission modeling analysis. Am J Epidemiol. 2013, 177: 1236-1245. 10.1093/aje/kws378.CrossRefPubMedPubMedCentral
40.
go back to reference Kalkowska DA, Duintjer Tebbens RJ, Thompson KM: Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria. J Infect Dis. 2014, (In press). doi:10.1093/infdis/jit834 Kalkowska DA, Duintjer Tebbens RJ, Thompson KM: Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria. J Infect Dis. 2014, (In press). doi:10.1093/infdis/jit834
41.
go back to reference Thompson KM, Duintjer Tebbens RJ: Current polio global eradication and control policy options: perspectives from modeling and prerequisites for OPV cessation. Expert Reviews of Vaccines. 2012, 11: 449-459. 10.1586/erv.11.195.CrossRef Thompson KM, Duintjer Tebbens RJ: Current polio global eradication and control policy options: perspectives from modeling and prerequisites for OPV cessation. Expert Reviews of Vaccines. 2012, 11: 449-459. 10.1586/erv.11.195.CrossRef
42.
go back to reference Lowther SA, Roesel S, O’Connor P, Landaverde M, Oblapenko G, Deshevoi S, Ajay G, Buff A, Safwat H, Salla M, et al: World Health Organization regional assessments of the risks of poliovirus outbreaks. Risk Anal. 2013, 33: 664-679. 10.1111/risa.12032.CrossRefPubMed Lowther SA, Roesel S, O’Connor P, Landaverde M, Oblapenko G, Deshevoi S, Ajay G, Buff A, Safwat H, Salla M, et al: World Health Organization regional assessments of the risks of poliovirus outbreaks. Risk Anal. 2013, 33: 664-679. 10.1111/risa.12032.CrossRefPubMed
43.
go back to reference Thompson KM, Duintjer Tebbens RJ: Modeling the dynamics of oral poliovirus vaccine cessation. J Infect Dis. 2014, (In press). doi:10.1093/infdis/jit845 Thompson KM, Duintjer Tebbens RJ: Modeling the dynamics of oral poliovirus vaccine cessation. J Infect Dis. 2014, (In press). doi:10.1093/infdis/jit845
44.
go back to reference Kidd S, Goodson JL, Aramburu J, Morais A, Gaye A, Wannemuehler K, Buffington J, Gerber S, Wassilak S, Uzicanin A: Poliomyelitis outbreaks in Angola genetically linked to India: risk factors and implications for prevention of outbreaks due to wild poliovirus importations. Vaccine. 2011, 29: 3760-3766. 10.1016/j.vaccine.2011.03.034.CrossRefPubMed Kidd S, Goodson JL, Aramburu J, Morais A, Gaye A, Wannemuehler K, Buffington J, Gerber S, Wassilak S, Uzicanin A: Poliomyelitis outbreaks in Angola genetically linked to India: risk factors and implications for prevention of outbreaks due to wild poliovirus importations. Vaccine. 2011, 29: 3760-3766. 10.1016/j.vaccine.2011.03.034.CrossRefPubMed
45.
go back to reference Centers for Disease C, Prevention: Notes from the field: outbreak of poliomyelitis--Somalia and Kenya, May 2013. Morb Mortal Wkly Rep. 2013, 62: 484- Centers for Disease C, Prevention: Notes from the field: outbreak of poliomyelitis--Somalia and Kenya, May 2013. Morb Mortal Wkly Rep. 2013, 62: 484-
Metadata
Title
The potential impact of expanding target age groups for polio immunization campaigns
Authors
Radboud J Duintjer Tebbens
Dominika A Kalkowska
Steven GF Wassilak
Mark A Pallansch
Stephen L Cochi
Kimberly M Thompson
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2014
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-14-45

Other articles of this Issue 1/2014

BMC Infectious Diseases 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.